Explore

Trendline Trendline
Bayer's $2.45 Billion Acquisition of Perfuse Therapeutics Aims to Revolutionize Eye Disease Treatment

Bayer's $2.45 Billion Acquisition of Perfuse Therapeutics Aims to Revolutionize Eye Disease Treatment

Bayer's $2.45 Billion Acquisition of Perfuse Therapeutics Aims to Revolutionize Eye Disease Treatment
Trendline Trendline
UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease
Trendline Trendline
PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities with $1 Billion Investment

PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities with $1 Billion Investment

PCI Pharma Services Expands U.S. Sterile Fill/Finish Capabilities with $1 Billion Investment
Trendline Trendline
Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones

Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones

Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
Trendline Trendline
UCB to Acquire Candid Therapeutics for $2.2 Billion, Expanding TCE Antibody Portfolio

UCB to Acquire Candid Therapeutics for $2.2 Billion, Expanding TCE Antibody Portfolio

UCB to Acquire Candid Therapeutics for $2.2 Billion, Expanding TCE Antibody Portfolio
Trendline Trendline
UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline
Trendline Trendline
UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies